Literature DB >> 16914509

Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak.

Louise Melencio1, Robert J McKallip, Hongbing Guan, Rupal Ramakrishnan, Reena Jain, Prakash S Nagarkatti, Mitzi Nagarkatti.   

Abstract

T regulatory cells (CD4(+)CD25(+)) play an important role in the regulation of the immune response. However, little is known about the ability of T regulatory cells to regulate endothelial cell (EC) damage following activation of lymphocytes with IL-2. Therefore, in the current study, we examined the role of T regulatory cells and the subsequent T(h)1/T(h)2 bias in IL-2-mediated EC injury using the well-characterized C57BL/6 (T(h)1-biased) and BALB/c (T(h)2-biased) models. Following IL-2 treatment, BALB/c mice were less susceptible to IL-2-induced vascular leak syndrome (VLS) compared with C57BL/6 mice. Splenocytes from BALB/c mice displayed less cytotoxicity against ECs compared with those from C57BL/6 mice. Interestingly, BALB/c mice had significantly higher numbers of CD4(+)CD25(+) T regulatory cells, which proliferated more profoundly following IL-2 treatment, compared with CD4(+)CD25(+) T regulatory cells from C57BL/6 mice. In addition, T regulatory cells from naive BALB/c mice were more potent suppressors of anti-CD3 mAb-stimulated proliferation of T cells than similar cells from C57BL/6 mice. Depletion of T regulatory cells in both BALB/c and C57BL/6 mice led to a significant increase in IL-2-induced VLS. Together, the results from this study suggest that CD4(+)CD25(+) T regulatory cells play an important role in the regulation of IL-2-induced EC injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914509     DOI: 10.1093/intimm/dxl079

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  12 in total

1.  Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury.

Authors:  Sadiye Amcaoglu Rieder; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injury.

Authors:  Sadiye Amcaoglu Rieder; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

3.  Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Authors:  Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

4.  Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Authors:  Timothy Kottke; Rosa M Diaz; Karen Kaluza; Jose Pulido; Feorillo Galivo; Phonphimon Wongthida; Jill Thompson; Candice Willmon; Glen N Barber; John Chester; Peter Selby; Scott Strome; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

5.  Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.

Authors:  Timothy Kottke; Feorillo Galivo; Phonphimon Wongthida; Rosa Maria Diaz; Jill Thompson; Dragan Jevremovic; Glen N Barber; Geoff Hall; John Chester; Peter Selby; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-04-22       Impact factor: 11.454

6.  The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis.

Authors:  Michael Rouse; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Immunobiology       Date:  2012-08-09       Impact factor: 3.144

7.  A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice.

Authors:  Dongeun Huh; Daniel C Leslie; Benjamin D Matthews; Jacob P Fraser; Samuel Jurek; Geraldine A Hamilton; Kevin S Thorneloe; Michael Allen McAlexander; Donald E Ingber
Journal:  Sci Transl Med       Date:  2012-11-07       Impact factor: 17.956

8.  Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma.

Authors:  Hongbing Guan; Narendra P Singh; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

9.  Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.

Authors:  P L Triozzi; W Aldrich; S Ponnazhagan
Journal:  Cancer Gene Ther       Date:  2011-08-26       Impact factor: 5.987

10.  Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Authors:  Hélène Bugaut; Mélanie Bruchard; Hélène Berger; Valentin Derangère; Ludivine Odoul; Romain Euvrard; Sylvain Ladoire; Fanny Chalmin; Frédérique Végran; Cédric Rébé; Lionel Apetoh; François Ghiringhelli; Grégoire Mignot
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.